Lorcaserin
A selective serotonin receptor agonist that reduced appetite by activating satiety pathways, withdrawn in 2020 after long-term safety review.
Plain English
Patient-Friendly Explanation
Lorcaserin is a weight loss medication that works by activating specific serotonin receptors in the brain to reduce appetite and increase feelings of fullness after eating smaller portions. It was designed to help patients feel satisfied with less food, supporting long-term dietary changes. While no longer available in some markets due to safety concerns identified in post-marketing studies, it remains an important example of how appetite-regulating medications are developed and evaluated.
Medical
Clinical Definition
Lorcaserin (Belviq) is a selective 5-HT2C serotonin receptor agonist that activates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus of the hypothalamus. This stimulates the melanocortin pathway, promoting satiety and reducing food intake. It was FDA-approved in 2012 for chronic weight management but was voluntarily withdrawn in 2020 after the CAMELLIA-TIMI 61 trial showed an increased cancer risk over extended use, highlighting the importance of long-term pharmacovigilance in obesity medicine.
Key Insight
Why It Matters
Lorcaserin demonstrates the scientific principle of targeted appetite suppression via serotonin pathways, a concept that continues to inform newer weight loss medications. Understanding its mechanism and withdrawal teaches patients the importance of evidence-based pharmacotherapy and regular medical follow-up during weight management.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: August 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.
